The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. (Q50648854)

17 March 2018

title

The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. (English)

1 reference

17 March 2018

1 reference

7

1 reference

17 March 2018

Julien Dumurgier

object named as

Julien Dumurgier

1

0 references

Jacques Hugon

8

object named as

Jacques Hugon

1 reference

17 March 2018

Jean-Louis Laplanche

2

1 reference

17 March 2018

Francois Mouton-Liger

3

1 reference

17 March 2018

Pauline Lapalus

4

1 reference

17 March 2018

Sandrine Indart

5

1 reference

17 March 2018

Magali Prévot

6

1 reference

17 March 2018

Claire Paquet

9

1 reference

17 March 2018

publication date

12 April 2014

1 reference

17 March 2018

published in

Journal of Neurology

1 reference

17 March 2018

volume

261

1 reference

17 March 2018

issue

6

1 reference

17 March 2018

page(s)

1187-1195

1 reference

17 March 2018

Classification and basic pathology of Alzheimer disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Revised research diagnostic criteria for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Regulatory innovation and drug development for early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Apolipoprotein E in Alzheimer's disease and other neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

CSF biomarker variability in the Alzheimer's Association quality control program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer's diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Recent advances in the genetics of the ALS-FTLD complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Gender and age modify the association between APOE and AD-related neuropathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7335-6

Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study.

21 January 2018

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

12 December 2020

CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.

1 reference

12 December 2020

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

1 reference

12 December 2020

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

1 reference

12 December 2020

Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels

1 reference

12 December 2020

10.1007/S00415-014-7335-6

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018